Cells from more than 30% of human cancers have been shown to contain point mutants of ras proteins. Residues 12, 13, 59, 61, 63, 116, 117, 119 and 146 of the proteins belong to all of the known mutation sties identified either in mammalian tumor or in transformed mammalian cells. The overall objective is to correlate biochemical and biological consequences of the oncogenic mutations with the structural changes associated with the mutations. We propose to construct, to determine the crystal structures of, and to characterize the mutants that are either the same as those found in various mammalian tumors or important for illuminating the structural basis for understanding biochemical and biological properties of the mutants. Experimental methods used will involve (a) x-ray crystallographic methods to determine the crystal structures of the normal and the mutants complexed with GDP, non-hydrolyzable GTP analogs, or a transition state analog; (b) in vitro biochemical characterization of GTP hydrolysis and GDP/GTP exchange rates using radiolabelled guanine nucleotides; and (c) microinjection of purified proteins into frog oocytes for in vivo assay of the transforming activity of the various mutant ras proteins.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA045593-07
Application #
3188718
Study Section
Molecular and Cellular Biophysics Study Section (BBCA)
Project Start
1987-08-01
Project End
1996-07-31
Budget Start
1993-08-01
Budget End
1994-07-31
Support Year
7
Fiscal Year
1993
Total Cost
Indirect Cost
Name
University of California Berkeley
Department
Type
Schools of Arts and Sciences
DUNS #
094878337
City
Berkeley
State
CA
Country
United States
Zip Code
94704
Phillips, K; Phillips, S E (1994) Electrostatic activation of Escherichia coli methionine repressor. Structure 2:309-16
Langen, R; Schweins, T; Warshel, A (1992) On the mechanism of guanosine triphosphate hydrolysis in ras p21 proteins. Biochemistry 31:8691-6
Prive, G G; Milburn, M V; Tong, L et al. (1992) X-ray crystal structures of transforming p21 ras mutants suggest a transition-state stabilization mechanism for GTP hydrolysis. Proc Natl Acad Sci U S A 89:3649-53
Tong, L A; de Vos, A M; Milburn, M V et al. (1991) Crystal structures at 2.2 A resolution of the catalytic domains of normal ras protein and an oncogenic mutant complexed with GDP. J Mol Biol 217:503-16
Milburn, M V; Tong, L; deVos, A M et al. (1990) Molecular switch for signal transduction: structural differences between active and inactive forms of protooncogenic ras proteins. Science 247:939-45
Brunger, A T; Milburn, M V; Tong, L et al. (1990) Crystal structure of an active form of RAS protein, a complex of a GTP analog and the HRAS p21 catalytic domain. Proc Natl Acad Sci U S A 87:4849-53
Rine, J; Kim, S H (1990) A role for isoprenoid lipids in the localization and function of an oncoprotein. New Biol 2:219-26
Schafer, W R; Kim, R; Sterne, R et al. (1989) Genetic and pharmacological suppression of oncogenic mutations in ras genes of yeast and humans. Science 245:379-85
Holbrook, S R; Kim, S H (1989) Molecular model of the G protein alpha subunit based on the crystal structure of the HRAS protein. Proc Natl Acad Sci U S A 86:1751-5
de Vos, A M; Tong, L; Milburn, M V et al. (1988) Three-dimensional structure of an oncogene protein: catalytic domain of human c-H-ras p21. Science 239:888-93

Showing the most recent 10 out of 12 publications